Patients with clopidogrel loss-of-function gene patterns who received a stent for acute myocardial infarction saw a sharp decline in ischemic events in one year as a result of genotype-guided antiplatelet therapy, according to the GIANT trial. The trial included 316 patients with the LOF genotype, 86% of whom had their prescribed antiplatelet therapy adjusted in response to assay results. The one-year composite risk of death, heart attack or stent thrombosis was similar to that of patients who didn't have the high-risk genotype, according to the study, while the end point composite was five times higher for those whose therapy was not changed based on the findings.

Related Summaries